An observational study in Infertility, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 36 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.
Among the 139 studies in Infertility with a site in China, this one is the 25th largest by planned enrollment of the 32 observational ones that give a count, is one of 8 that started in 2026, is one of 32 observational ones, reaches primary completion later than 37 of the 40 other live ones, and was the 134th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 20–40 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Sites in China
Ages 20–40 · Women only
Tang-Du Hospital · Sites in China
Ages 20–45 · Women only
Li-jun Ding · Sites in China
Ages 18–39 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 36 Years to 39 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 15 · Phase 4 14
First in 2003; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 592 observational studies indexed under Infertility.
Median enrollment 248 across the 107 interventional studies, 550 across the 32 observational. Of the 56 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 139 have an industry lead sponsor. The 10 most frequent:
Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.
Changchun GeneScience Pharmaceutical Co., Ltd. has 4 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
12 of the studies in Infertility with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07696351Li-jun DingUltra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis | 2026-12-31 |
| NCT07050537The First Affiliated Hospital with Nanjing Medical UniversityA Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology | 2027-03-31 |
| NCT07533630Reproductive & Genetic Hospital of CITIC-XiangyaProspective International Multi-center Clinical Trial of PGT-A Upgrade | 2027-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 139 studies in Infertility with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-centre, single-arm, observational trial to assess the safety and efficacy of corifollitropin alfa N02 Injection in elderly Chinese women undergoing ART, and then to explore the compliance and satisfaction during COS treatment.
Married women aged 36-39 years scheduled for controlled ovarian stimulation (COS) and IVF/ICSI assisted reproduction using a fixed antagonist protocol with Corifollitropin alfa N02 Injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
High risk of ovarian hyperstimulation syndrome (OHSS), defined by any of the following:
Diagnosed with polycystic ovary syndrome (PCOS);
Poor ovarian function, defined by any of the following:
① Previous poor ovarian response (≤3 oocytes retrieved following conventional full-dose gonadotropin stimulation);
② Total AFC in both ovaries \<5.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Observe and record the safety and efficacy data of women receiving controlled ovarian stimulation therapy using Corifollitropin alfa N02 Injection
Other: NA,Observational study
Data will be collected without interfering with routine clinical care.
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: From signing the ICF to the birth of the newborn
Incidence of early-onset ovarian hyperstimulation syndrome (OHSS)
Time frame: Up to 9 days after triggering of final follicular maturation
Incidence of moderate to severe OHSS
Time frame: Up to 10-11 weeks after transfer
fetal/newborn birth defects
Time frame: Up to 15 months
1-year cumulative clinical pregnancy rate per initiated stimulation cycles
Time frame: 4 to 6 weeks after last frozen embryo transfer
1-year cumulative ongoing pregnancy rate per initiated stimulation cycles
Time frame: 9 to 11 weeks after last frozen embryo transfer
1-year cumulative live birth rate per initiated stimulation cycles
Time frame: more than 40 weeks after last frozen embryo transfer
β-hCG/hCG positive rate per initiated stimulation cycles with fresh embryo transfer
Time frame: 4 weeks after fresh embryo transfer
Clinical pregnancy rate per initiated stimulation cycles with fresh embryo transfer
Time frame: 4 to 6 weeks after fresh embryo transfer
Ongoing pregnancy rate per initiated stimulation cycles with fresh embryo transfer
Time frame: 9 to 11 weeks after fresh embryo transfer
Live birth rate per initiated stimulation cycles with fresh embryo transfer
Time frame: more than 40 weeks after fresh embryo transfer
β-hCG/hCG positive rate per initiated stimulation cycles with first embryo transfer cycle
Time frame: 4 weeks after first embryo transfer
Clinical pregnancy rate per initiated stimulation cycles with first embryo transfer cycle
Time frame: 4 to 6 weeks after first embryo transfer
Ongoing pregnancy rate per initiated stimulation cycles with first embryo transfer cycle
Time frame: 9 to 11 weeks after first embryo transfer
Live birth rate per initiated stimulation cycles with first embryo transfer cycle
Time frame: more than 40 weeks after first embryo transfer
Pregnancy loss rate
Time frame: Up to 38 weeks after transfer
Number of oocytes retrieved
Time frame: Up to 22 days
Estrogen (E₂) and progesterone (P) levels during controlled ovarian stimulation (COS)
Time frame: Up to 22 days
Follicular development status
Time frame: Up to 22 days
Metaphase II (MII) oocyte rate [evaluated only in intracytoplasmic sperm injection (ICSI) cycles]
Time frame: Up to 22 days
Fertilization rate Implantation rate
Time frame: Day 3 after oocyte retrieval
Implantation rate
Time frame: Up to 28 days
High-quality embryo rate
Time frame: Day 3 after oocyte retrieval
Usable blastocyst formation rate
Time frame: Day 5 after oocyte retrieval
Started Apr 2026 (actual). Primary completion is estimated for Aug 2029, 39 months after the start.
Of 240 observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 39 months is close to that.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changchun GeneScience Pharmaceutical Co., Ltd. →